title: Drug repositioning in the treatment of malaria and TB.
abstract: The emergence and spread of drug resistance in the malaria parasite Plasmodium falciparum as well as multi- and extremely drug-resistant forms of Mycobacterium tuberculosis, the causative agent of TB, could hamper the control of these diseases. For instance, there are indications that the malaria parasite is becoming resistant to artemisinin derivatives, drugs that form the backbone of antimalarial combination therapy. Likewise, Mycobacterium tuberculosis strains that are multidrug-resistant or extremely drug-resistant to first- and second-line drugs have been associated with increased mortality. Thus, more than ever, new antimalarials and anti-TB drugs are needed. One of the strategies to discover new drugs is to reposition or repurpose existing drugs, thus reducing the cost and time of drug development. In this review, we discuss how this concept has been used in the past to discover antimalarial and anti-TB drugs, and summarize strategies that can lead to the discovery and development of new drugs.
authors: University of Cape Town, Department of Chemistry, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Rondebosch 7701, South Africa. alex.nzila@uct.ac.za
authors: Alexis
authors: A
authors: Nzila
authors: Zhenkun
authors: Z
authors: Ma
authors: Kelly
authors: K
authors: Chibale
mesh_terms: D000818:Animals; D000962:Antimalarials / Q000008:administration & dosage / Q000627:therapeutic use*; D000995:Antitubercular Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D055808:Drug Discovery / Q000379:methods*; D058492:Drug Repositioning; D004359:Drug Therapy, Combination; D006801:Humans; D008288:Malaria / Q000188:drug therapy*; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
chemical_list: D000962:Antimalarials; D000995:Antitubercular Agents